Zimmer Biomet Holdings Inc. Stock Rises 3.4%, Outperforms Market
Dow Jones2026/10/12 20:35This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Zimmer Biomet Holdings Inc. rallied 3.4% to $92.17 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.4% to 51,850.55 and the S&P 500 Index falling 0.1% to 7,807.24.
This was the stock's third consecutive day of gains.
Zimmer Biomet Holdings Inc. closed 13.8% below its 52-week high of $106.88, which the company reached on October 22nd.
The stock demonstrated a mixed performance when compared to some of its peers, as Johnson & Johnson rose 0.9% to $263.73, Medtronic PLC rose 3.9% to $91.93, and Stryker Corp. rose 1.90% to $282.60.
Trading volume totaled 1.8 million, compared to the 50-day average of 2.1 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 12, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
BUZZ-3M India shares fall to 19-month low due to quarterly profit decline
Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.
After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.
Crypto prices
More
